Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP5 | P45974 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437051 | 0.86 | NAMPT (0.46) | ALDH1A1KMT2AMEN1PKMTSHR | |
| SCHEMBL24571567 | 0.86 | NAMPT (0.46) | ALDH1A1KMT2AMEN1PKMTSHR | |
| SCHEMBL29077548 | 0.82 | HTR2C (0.48) | ALDH1A1KMT2AMEN1EPHX2HTR2C | |
| SCHEMBL24571898 | 0.78 | KMT2A (0.42) | ALDH1A1KMT2AMEN1PKMHTR2C | |
| SCHEMBL31437042 | 0.77 | UTS2R (0.47) | ALDH1A1KMT2AMEN1PKMEPHX2 | |
| SCHEMBL24571700 | 0.77 | UTS2R (0.47) | ALDH1A1KMT2AMEN1PKMEPHX2 | |
| SCHEMBL24571634 | 0.74 | BRD4 (0.43) | ALDH1A1KMT2AMEN1PKMTSHR | |
| SCHEMBL29077479 | 0.73 | HTR2C (0.47) | ALDH1A1KMT2AMEN1HTR2CUSP5 | |
| SCHEMBL23270984 | 0.73 | MEN1 (0.75) | ALDH1A1KMT2AMEN1PKMTSHR | |
| SCHEMBL24571532 | 0.73 | NAMPT (0.52) | ALDH1A1KMT2AMEN1PKMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267575-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |